---
figid: PMC5611863__nihms897656f2
figtitle: Landscape of new drugs in lymphoma
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
pmcid: PMC5611863
filename: nihms897656f2.jpg
figlink: /pmc/articles/PMC5611863/figure/F2/
number: F2
caption: Several small-molecule inhibitors targeting different nodes in this pathway
  are under development for the treatment of cancer. Currently, idelalisib, which
  selectively targets the PI3Kδ isoform, is the only PI3K inhibitor to be approved
  by regulatory agencies is idelalisib.
papertitle: The landscape of new drugs in lymphoma.
reftext: Anas Younes, et al. Nat Rev Clin Oncol. ;14(6):335-346.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9278883
figid_alias: PMC5611863__F2
figtype: Figure
redirect_from: /figures/PMC5611863__F2
ndex: 667c616d-deac-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5611863__nihms897656f2.html
  '@type': Dataset
  description: Several small-molecule inhibitors targeting different nodes in this
    pathway are under development for the treatment of cancer. Currently, idelalisib,
    which selectively targets the PI3Kδ isoform, is the only PI3K inhibitor to be
    approved by regulatory agencies is idelalisib.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - cass
  - sgg
  - foxo
  - Akt
  - p53
  - betaTub60D
  - hth
  - Crtc
  - S6k
  - Thor
  - Temsirolimus
  - Ridaforolimus
  - Cancer
---
